Targeted therapies combining antibody specificity with cytotoxic payloads via chemical linkers. The ADC field is experiencing explosive growth with next-generation linker-payload technologies and novel targets beyond oncology.
Lilly bets on next-generation dual-payload ADCs with the acquisition of CrossBridge Bio, whose CBB-120 platform delivers two cytotoxic agents per antibody for potentially superior tumor killing.
Apr 15, 2026 · 4 min read
The antibody-drug conjugate market has grown from $16B in 2025 to over $20B in 2026, fueled by Gilead's $5B Tubulis acquisition and Lilly's CrossBridge Bio deal. A deep dive into next-gen linker-payload chemistry, dual-payload designs, and which tumor types remain white space.
Apr 15, 2026 · 12 min read
Gilead enters a definitive agreement to acquire German biotech Tubulis for $3.15B upfront plus $1.85B in milestones. The deal adds best-in-class ADC linker-payload technology and creates a dedicated Munich R&D hub as the ADC sector surpasses $20B.
Apr 7, 2026 · 5 min read